Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults Post author:Sam Post published:June 15, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Genentech’s Frontline Alecensa Approved for Non-Small Cell Lung Cancer November 6, 2017 Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech February 11, 2018 How This Drug Candidate Could be a Winner in Gilead's Pipeline March 20, 2017